SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aer Therapeutics Reports Phase 2a Fexlamose Trial Results in COPD

The company said a 90 mg daily nebulized dose of fexlamose did not improve trough F.

Related stories